Sun, Oct 4, 2015
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Melanion Capital launches first hedge fund focused on dividend futures

Monday, July 08, 2013
Opalesque Industry Update - Melanion Capital, Paris has received authorization from the French Autorité des Marchés Financiers to become the first alternative manager to specialize in investment in dividend futures.

Led by Jad Comair, founder and CIO, the Melanion team traces its track record and expertise in dividend futures (at a leading French investment bank) from 2008, the year of the first listing of a dividend future on Eurex. Since 2008, the dividend futures market has expanded in volume, in the number of traded instruments (single stocks, indices, options, etc), the number of exchanges issuing these contracts (Eurex, NYSE Euronext, MEFF, LSE, Tokyo, Singapore etc.) and the number of market participants (institutions, banks, family offices and others).

Other members of the Melanion team include : Portfolio Manager : Antoine Iskandar, Risk Manager: Dr Bing Zhou, and Business Development Manager : Erwan Tigreat.

Since inception in 2008, the trading strategy employed by Melanion Capital has generated an average gross return of 20%+ per annum, compared to a 2% average decline in the EuroStoxx50 during the same period as the impact of the global financial crisis took hold.

“This strong demonstration of alpha generation is a key validation of the Melanion Capital investment approach,” said Founder and Chief Investment Officer, Jad Comair who went on to explain that his firm will employ: “Quant and fundamental elements including bottom-up analysis, stock-picking, yield strategies and arbitrage to achieve its performance objectives.

“Because they’re simple, easy to understand and answers investors’ need to hedge their dividend exposure, dividend futures have become very popular since 2008 in an environment where other assets were losing momentum after the financial crisis. Melanion Capital’s unique business model aims at capturing the opportunities in these derivatives while seeing them become the asset class of the next decade,” Jad Comair added. “Our investment team was there at the beginning and established itself through the difficult days of 2008 and 2010. We firmly believe that Melanion Capital embodies a ‘first mover advantage’ in this sector and we look forward to being able to demonstrate our strengths and our ability to create alpha, on behalf of investors, in a wide range of market conditions.”

Press release


What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing

  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Performance - Hedge fund moguls Einhorn, Loeb, Rosenstein lose money in September, Risky strategy sinks small hedge fund[more]

    Hedge fund moguls Einhorn, Loeb, Rosenstein lose money in September From Billionaire stock pickers David Einhorn, Daniel Loeb and Barry Rosenstein on Wednesday told their wealthy investors they lost money in September as market turmoil inflicted more pain on some of America'

  2. Opalesque Exclusive: IRAs represent billions of untapped capital for hedge funds[more]

    Benedicte Gravrand, Opalesque Geneva: Retirement accounts might not be the first source that comes to mind for those looking to raise funds, but they may represent billions of untapped capital. Unlike traditional retirement accounts,

  3. Opalesque TV: One way to access market hedge funds in the EU under the AIFMD radar[more]

    Benedicte Gravrand, Opalesque Geneva: While the Cayman Islands, the US and Hong Kong await the pan-European marketing passport to be extended to alternative investment fund

  4. Investing - U.S. biotech bloodbath hits hedge funds but some bargains emerge, Computer-driven hedge funds betting on further stock selloff[more]

    U.S. biotech bloodbath hits hedge funds but some bargains emerge From A seven-day selloff of U.S. biotechnology stocks has hit sector investors - especially hedge funds - hard. But some managers say it was overdone and are already eyeing bargains such as Gilead Sciences Inc

  5. Vilas’ equity long bias hedge fund generates market-beating results[more]

    Komfie Manalo, Opalesque Asia: The Vilas Fund, an equity long bias fund managed by Chicago, Illinois-based Vilas Capital Management, posted five-year annualized returns, net of fees, of 23.47% vs. 15.87% for the S&P 500 Index, including divid